Stoke Therapeutics, Inc.STOKNASDAQ
Loading
EV/EBITDA Over TimeContracting
Percentile Rank13
Studio
Year-over-Year Change

Enterprise value to EBITDA ratio

Latest
-95.40
↓ 180% vs avg
Percentile
P13
Within normal range
Streak
2 yr
Consecutive declineContracting
Average
-34.03
Historical baseline
PeriodValueYoY Change
2025-95.40-1913.2%
2024-4.74-1166.1%
2023-0.37+84.5%
2022-2.41+72.2%
2021-8.67+75.6%
2020-35.53-295.3%
2019-8.99+77.2%
2018-39.45+64.4%
2017-110.71-